What Is The Success Rate Of Car T-Cell Therapy Treatment 
                     https://www.edhacare.com/ 
What Is The Success Rate Of Car 
T-Cell Therapy Treatment ?
Cancer Treatment
Table of Contents
1. What is CAR-T Cell Therapy? 5.  Success Rate in Hematologic 
Cancers
2. How Does It Work?
6.  Factors Influencing Success Rate
3. Success Of Car T-Cell Therapy
7.  Efficacy Of CAR T-Cell Therapies
4. Importance of Success Rate in 
Cancer Treatment 8.  Conclusion
https://www.edhacare.com/treatments/cancer/car-t-c
ell-therapy
 
What is CAR-T Cell Therapy?
● A form of immunotherapy that modifies 
T-cells to attack cancer.
Car T-Cell Therapy Is  primarily used for 
blood cancers like leukemia and 
lymphoma.
How Does It Work?
T-cells are isolated, engineered, and then 
returned to the patient's body for the 
destruction of cancerous cells.
https://www.edhacare.com/treatments/cancer/car-t
-cell-therapy
 
Success Of Car T-Cell Therapy
CAR T-cell therapy (Chimeric Antigen 
Receptor T-cell therapy) has shown 
promising results as a treatment. Especially 
in patients who have relapsed or are 
refractory to other treatments. The success 
rate of CAR T-cell therapy can vary 
depending on several factors, including the 
specific type of CAR T-cell therapy used, the 
patient's overall health, and how advanced 
the disease is.
https://www.edhacare.com/treatments/cancer/car-t-c
ell-therapy
 
Importance of Success Rate in Cancer Treatment
● Treatment Effectiveness: Guides selection of the most effective therapies based on 
cancer type and stage.
● Patient Prognosis: Helps patients understand their chances of recovery and set 
realistic expectations.
● Emotional Impact: Provides hope for positive outcomes and prepares patients for 
realistic expectations.
● Resource Allocation: Helps prioritize effective treatments for better healthcare 
planning and policy.
https://www.edhacare.com/treatments/cancer/car-t-c
ell-therapy
 
Success Rate in Hematologic Cancers
1. Leukemia 
Acute Lymphoblastic Leukemia (ALL):
● Children have an 85-90% 5-year survival rate, while adults have lower 
rates due to complex disease.
Chronic Myeloid Leukemia (CML):
● Over 90% 5-year survival rate, thanks to the effectiveness of Tyrosine 
Kinase Inhibitors (TKIs), making it manageable long-term.
https://www.edhacare.com/treatments/cancer/car-t-c
ell-therapy
 
2 . Lymphoma
Hodgkin Lymphoma:
● High 5-year survival rate of about 87%, with excellent outcomes, 
especially in younger patients.
Non-Hodgkin Lymphoma (NHL):
● 5-year survival rate ranges from 60-80%, depending on subtype and 
stage of diagnosis.
https://www.edhacare.com/treatments/cancer/car-t-c
ell-therapy
 
Factors Influencing Success 
Rate
➔ Pre-treatment disease burden: Patients 
with less aggressive or smaller disease 
burden may have better outcomes.
➔ Age and overall health: Older patients 
or those with other comorbidities may 
experience more complications or side 
effects. Tip
➔ Previous treatments: The success of Factors influencing CAR T-
CAR-T can depend on how many lines of cell  therapy success 
therapy a patient has already undergone include cancer type, 
patient's overall health, 
and their response to those treatments. age, immune system 
status, cancer stage, 
treatment resistance, 
specific CAR T-cell product 
used, and potential side 
https://www.edhacare.com/treatments/c effects.
ancer/car-t-cell-therapy
 
Efficacy Of CAR T-Cell Therapies:
In clinical trials, Abecma showed that approximately 
73% of patients with heavily pretreated multiple 
myeloma achieved a complete or partial response to 
the therapy. Among these, about 33% achieved a 
stringent complete response .
The overall response rate (ORR) was around 73-80% in 
various clinical settings, with the duration of response 
varying but lasting several months to years in some 
cases.
https://www.edhacare.com/treatments/cancer/car-t-
cell-therapy
 
https://www.edhacare.com/treatments/cancer/car-t-
cell-therapy
 
Conclusion
CAR T-cell therapy has shown a high success rate for treating particularly in 
patients who have failed other treatments. 
Success rates vary depending on individual factors, but response rates of 
70–80% are typical, with complete response rates of 33–67% in clinical trials.
CAR-T Therapy is highly successful in treating blood cancers, with remission 
rates of 80-90% in some cases.
A promising future for CAR-T in expanding treatment options for various cancers.
Tip
CAR T-cell therapy 
shows high success 
rates for blood 
cancers, particularly 
leukemia and 
lymphoma, with 
remission rates up to 
80- 90%.
https://www.edhacare.com/treatments/cancer/car-t
-cell-therapy
 
https://www.edhacare.com/treatments/cancer/car-t-ce
ll-therapy